|
Dear Edson Neto, |
Based on the papers you've read, we think you might be interested in this recently published article from Academia Oncology: Advances in PD-1/PD-L1 inhibitor combinations with standard therapies for hematological malignancies
|
| Hematological malignancies clinically encompass common subtypes including leukemia, lymphoma, and multiple myeloma, and their overall incidence has shown an increasing trend in recent years. As a type of immune checkpoint inhibitor (ICI), programmed death protein-1 (PD-1)/programmed death ligand 1 (PD-L1) inhibitors... Read more |
|
|
|---|
|
|
Academia Oncology is an innovative open access journal publishing original research and review articles covering all areas of oncology. The editors welcome interdisciplinary submissions from the cutting edge of oncology research, in particular, those that drive connectivity between disciplines. |
|
|
|---|
|
|
|
|
Read later